6-chlorooxazolo[5,4-b]pyridine-2-thiol | 1206716-59-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶唑并吡啶类
• 英文名称: 6-chlorooxazolo[5,4-b]pyridine-2-thiol
• 英文别名: 6-Chlorooxazolo[5,4-b]pyridine-2(1H)-thione；6-chloro-1H-[1,3]oxazolo[5,4-b]pyridine-2-thione
• CAS: 1206716-59-7
• 化学式: C₆H₃ClN₂OS
• 分子量: 186.622
• InChiKey: JDGPCXUFHHIBJU-UHFFFAOYSA-N

物化性质

• 沸点：
  297.7±50.0 °C(Predicted)
• 密度：
  1.68±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-chlorooxazolo[5,4-b]pyridine-2-thiol 在 potassium carbonate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 N-[2-(6-chlorooxazolo[5,4-b]pyridin-2-yl)-2-azaspiro[3.3]heptan-6-yl]-5-methylsulfonylfuran-2-carboxamide
  参考文献：
  名称：

  [EN] N-[(1,3-BENZOXAZOL-2-YL)-HETEROCYCLE]AMIDE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION
  [FR] DÉRIVÉS DE N-[(1,3-BENZOXAZOL-2-YL)-HÉTÉROCYCLE]AMIDE POUR LE TRAITEMENT ET LA PROPHYLAXIE D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B

  摘要：

  本发明提供了具有一般式为(Formula I)的新化合物，其中A1至A4，X，Cy和R1如本文所述，包括该化合物的组合物和使用该化合物作为HBsAg抑制剂治疗HBV感染的方法。

  公开号：

  WO2022106680A1
• 作为产物：
  描述：

  硫光气 、 2-羟基-3-氨基-5-氯吡啶 以 四氢呋喃 为溶剂， 反应 1.5h， 以30%的产率得到6-chlorooxazolo[5,4-b]pyridine-2-thiol
  参考文献：
  名称：

  Discovery of 4-(5-Methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models

  摘要：

  A novel alpha 7 nAChR agonist, 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (24, CP-810,123), has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions including schizophrenia and Alzheimer's disease. Compound 24 is a potent and selective Compound with excellent pharmaceutical properties. In rodent, the compound displays high oral bioavailability and excellent brain penetration affording high levels of receptor occupancy and in vivo efficacy in auditory sensory gating and novel object recognition. The structural diversity of this compound and its preclinical in vitro and in vivo package support the hypothesis that alpha 7 nAChR agonists may have potential as a pharmacotherapy for the treatment of cognitive deficits in schizophrenia.

  DOI：

  10.1021/jm9015075

文献信息

• Discovery of 4-(5-Methyloxazolo[4,5-<i>b</i>]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models
  作者：Christopher J. O’Donnell、Bruce N. Rogers、Brian S. Bronk、Dianne K. Bryce、Jotham W. Coe、Karen K. Cook、Allen J. Duplantier、Edelweiss Evrard、Mihaly Hajós、William E. Hoffmann、Raymond S. Hurst、Noha Maklad、Robert J. Mather、Stafford McLean、Frank M. Nedza、Brian T. O’Neill、Langu Peng、Weimin Qian、Melinda M. Rottas、Steven B. Sands、Anne W. Schmidt、Alka V. Shrikhande、Douglas K. Spracklin、Diane F. Wong、Andy Zhang、Lei Zhang

  DOI：10.1021/jm9015075

  日期：2010.2.11

  A novel alpha 7 nAChR agonist, 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (24, CP-810,123), has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions including schizophrenia and Alzheimer's disease. Compound 24 is a potent and selective Compound with excellent pharmaceutical properties. In rodent, the compound displays high oral bioavailability and excellent brain penetration affording high levels of receptor occupancy and in vivo efficacy in auditory sensory gating and novel object recognition. The structural diversity of this compound and its preclinical in vitro and in vivo package support the hypothesis that alpha 7 nAChR agonists may have potential as a pharmacotherapy for the treatment of cognitive deficits in schizophrenia.
• [EN] N-[(1,3-BENZOXAZOL-2-YL)-HETEROCYCLE]AMIDE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION<br/>[FR] DÉRIVÉS DE N-[(1,3-BENZOXAZOL-2-YL)-HÉTÉROCYCLE]AMIDE POUR LE TRAITEMENT ET LA PROPHYLAXIE D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B
  申请人：HOFFMANN LA ROCHE

  公开号：WO2022106680A1

  公开（公告）日：2022-05-27

  The present invention provides novel compounds having the general formula: (Formula I) wherein A1to A4, X, Cy and R1are as described herein, compositions including the compounds and methods of using the compounds as HBsAg inhibitors for the treatment of HBV infection.

  本发明提供了具有一般式为(Formula I)的新化合物，其中A1至A4，X，Cy和R1如本文所述，包括该化合物的组合物和使用该化合物作为HBsAg抑制剂治疗HBV感染的方法。